NON-HODGKIN LYMPHOMA

This Phase 3 trial tests a new CAR T-cell therapy called ronde-cel, which targets two proteins (CD19 and CD20) on lymphoma cells, against the standard single-target CAR T therapy. The study involves 400 adults with large B-cell lymphoma that has returned or not responded after in…

This early-phase trial tests an oral drug called AS-1763 in adults with certain blood cancers (like CLL or lymphoma) that have not responded to at least two prior treatments. The main goals are to find the safest dose and see if the drug can shrink tumors. Around 120 participants…

This study looks at the long-term safety of pirtobrutinib in people with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma (NHL) who were already in an earlier trial. About 279 participants will continue their treatment or follow-up visits. The main goal is to track seri…

This early-stage study tests a new approach for people with certain lymphomas (like Hodgkin lymphoma) that have come back or not responded to standard treatments. Researchers take immune cells from healthy donors, add a special receptor (C7R) to help them survive longer, and targ…

This study gives people with blood cancers, immune disorders, and other serious diseases access to cord blood transplants that are not yet FDA-approved. It includes children and adults of any age. The main goal is to see how well the new blood cells grow after transplant.

This early-phase study tests a new type of CAR T cell therapy that targets two proteins (CD79b and CD19) on lymphoma cells. It is for people with non-Hodgkin lymphoma that has come back or not responded to standard treatments. The main goals are to check safety and find the right…

This early-phase study tests azer-cel, a pre-made (allogeneic) CAR T cell therapy, in adults with relapsed or refractory non-Hodgkin lymphoma, B-cell acute lymphoblastic leukemia, and related blood cancers. The goal is to check safety and see if these donor-derived cells can shri…

This study tests a new treatment called CTX112 for people with B-cell blood cancers (like lymphoma or leukemia) that have come back or not responded to standard therapy. CTX112 uses CRISPR gene-editing to create donor T-cells that target and kill cancer cells. The trial involves …

This study is for people with blood cancers like leukemia or lymphoma who need a stem cell transplant from an unrelated donor. It compares two ways to prevent graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. One method uses a d…

This study tests an experimental oral drug called LP-118 in up to 100 adults with blood cancers like leukemia, lymphoma, or multiple myeloma that have come back or not responded to other treatments. The main goals are to find the safest dose and see if the drug can shrink tumors …

This study tests a new drug called CCS1477 in people with advanced blood cancers like leukemia, lymphoma, and multiple myeloma that have not responded to standard treatments. The main goals are to check the drug's safety and find the right dose. About 250 participants will receiv…

This early-stage study tests a new gene therapy called VNX-101 for people with certain blood cancers (like leukemia and lymphoma) that have returned or not improved with standard treatments. The therapy uses a harmless virus to deliver a gene that helps the immune system attack c…

This study tests whether giving a targeted radiation drug (131I-Apamistamab) before standard CAR-T cell therapy can safely improve outcomes for people with relapsed or refractory diffuse large B-cell lymphoma. About 30 adults will receive the radiation dose followed by a commerci…

This study tests a stem cell transplant using a person's own cells to treat Hodgkin and non-Hodgkin lymphoma. It includes people with HIV. The goal is to see if a radiation-free treatment plan helps patients live longer without their cancer returning. About 150 adults will take p…

This early-phase trial is testing whether adding the drug pomalidomide to standard chemotherapy (with or without rituximab) is safe and effective for people with HIV who have certain aggressive lymphomas. About 25 adults with high-risk features will receive up to 6 cycles of trea…

This study tests whether adding the drug ibrutinib to standard chemotherapy can help control primary central nervous system lymphoma (PCNSL) in people who are not eligible for a stem cell transplant. About 30 adults with newly diagnosed PCNSL will receive the combination therapy.…

This study tests whether a cord blood transplant (using stem cells from donated umbilical cord blood) can help children and young adults up to age 26 with blood cancers like leukemia or lymphoma. Participants receive the transplant as their first or second treatment. The main goa…

This study tests a new drug called CHO-H01, alone or with lenalidomide, in people with a type of blood cancer called Non-Hodgkin lymphoma that has returned or not improved after standard treatments. The first part finds the safest dose, and the second part checks if the combinati…

This study tests a combination of five drugs (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, called ViPOR) in people whose B-cell lymphoma has returned or not improved after prior treatment. The goal is to see if this drug mix is safe and how well it works. Pa…

This program provides access to an experimental drug called AVM0703 for people with various solid tumors or blood cancers who have not responded to other treatments. It is available in the US upon a doctor's request. So far, 37 patients have received the drug, and side effects ha…

This early-phase study tests a new drug called SGR-1505 in about 98 adults with various B-cell blood cancers (like lymphoma and leukemia). The main goals are to check safety and find the best dose. Participants will receive the drug and be monitored for side effects and how the d…

This study is for people with B-cell blood cancers like lymphoma and leukemia. It tests a new drug, BGB-16673, that breaks down a protein helping cancer grow. The goal is to find the right dose and see if it is safe and shrinks tumors. About 146 people in China will take part.

This study tests a two-step method using lower doses of radiation and chemotherapy before a stem cell transplant for people with various blood cancers or bone marrow failure. The goal is to see if this gentler approach reduces the chance of dying from the transplant itself. About…

This study tests a refined cord blood transplant method for people with hard-to-treat blood cancers like leukemia and lymphoma. Participants receive chemotherapy and radiation before the transplant to kill cancer cells and prepare the body, then donor stem cells are infused to re…

This study is for adults with Non-Hodgkin lymphoma, a type of blood cancer. It tests a new drug called epcoritamab combined with other cancer medicines to see if it is safe and helps shrink tumors. About 496 people will take part at hospitals around the world. The goal is to find…

This study tests a new immune therapy for people with advanced B-cell lymphoma or leukemia that has returned or not responded to standard treatment. Researchers take a patient's own T-cells, add a special receptor (CAR) that targets the CD19 protein on cancer cells, and give them…

This early-stage trial tests a new treatment called GB5005 for adults with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and…

This early-phase study tests whether a personalized cell therapy (CAR-T cells) is safe for people with certain types of Non-Hodgkin lymphoma that have come back or not responded to standard treatments. Up to 36 participants will receive their own immune cells that have been genet…

This early-phase study tests a new type of cell therapy (CD19x22 CAR T) for adolescents and adults with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified to target two proteins on cancer cells. Th…

This early-stage trial tests a new type of CAR T cell therapy (TmCD19-IL18) in 24 people with CD19+ cancers like non-Hodgkin lymphoma that have come back or not responded to treatment. The study aims to find the safest dose and check for side effects, while also looking at how we…

This study tests an experimental drug called BGB-16673 in people with several types of B-cell cancers (like lymphoma and leukemia) that have come back or not responded to other treatments. The drug works by breaking down a protein (BTK) that helps these cancer cells grow. The tri…

This study tests a new combination of drugs (linperlisib plus chemotherapy and thalidomide) in 180 adults with relapsed or refractory non-Hodgkin lymphoma. The goal is to see if the combo can shrink tumors and control the disease. Participants must have certain lymphoma types and…

This early-stage study tests a new drug called AXT-1003 in 78 people with advanced non-Hodgkin lymphoma or solid tumors that have not responded to standard treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also watch for side effect…

This study tests a new treatment called ronde-cel for people with aggressive B-cell lymphoma that has come back or not improved after at least two prior therapies. The treatment uses a patient's own immune cells, modified to target two different markers on cancer cells. The goal …

This early-stage study tests a new type of stem cell transplant for children whose blood cancer or solid tumor has returned or is hard to treat. Doctors use a special method to remove certain immune cells from the donor's stem cells, then give a drug called zoledronate after tran…

This early study tests a new treatment called LV009 injection in 10 adults whose blood cancers (certain types of lymphoma or leukemia) have returned or not responded to standard therapy. The main goal is to check if the treatment is safe. Participants receive the injection and ar…

This study looks at a new approach to collect stem cells for transplant in people with multiple myeloma, Hodgkin lymphoma, or non-Hodgkin lymphoma. The goal is to see if using a standard drug alone, with a second drug only when needed, can collect enough stem cells while possibly…

This study tests whether adding ruxolitinib to the immunotherapy drug pembrolizumab is safe and effective for people with certain lymphomas that have come back or not responded to treatment. About 53 adults with Hodgkin or non-Hodgkin lymphoma will receive the combination. The go…

This study looks at the long-term safety of the drug pirtobrutinib in people with chronic lymphocytic leukemia or non-Hodgkin lymphoma. Participants have already completed an earlier pirtobrutinib study and can continue treatment or follow-up visits here. The main goal is to trac…

This early-stage study tests two experimental drug combinations for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The goal is to find safe doses and see if the combinations can shrink tumors. About 121 participants w…

This study tests whether a new form of the drug carmustine (without ethanol) causes fewer side effects than the standard version in lymphoma patients receiving a stem cell transplant. About 49 adults with Hodgkin or non-Hodgkin lymphoma who are already candidates for transplant w…

This early-phase study tests a new treatment for adults with B-cell blood cancers (like lymphoma) that have not responded to prior therapies. Participants receive a special type of immune cell (CAR T-cells) along with a targeted drug called pirtobrutinib, which is given before an…

This early-stage study tests a new treatment called PIC1 injection for adults with relapsed or refractory B-cell Non-Hodgkin lymphoma, a type of blood cancer that has not responded to standard therapies. The main goal is to check the safety of the injection and see how many patie…

This study tests whether combining two drugs, pirtobrutinib and venetoclax, can help control mantle cell lymphoma (MCL) that has returned or not responded to prior therapy. About 30 adults with confirmed MCL will take both pills by mouth. The goal is to see how many patients' tum…

This study tests a new oral drug called AZD3470 in people with certain blood cancers, including Hodgkin and non-Hodgkin lymphoma. The goal is to see if the drug is safe and works, either alone or with other cancer treatments. About 161 adults and adolescents will take part in thi…

This early-stage study tests an experimental drug called CC312 in about 44 adults with certain blood cancers (like lymphoma or leukemia) that have returned or stopped responding to standard treatments. The main goals are to check the drug's safety and find the best dose. Research…

This study tests whether Darzalex Faspro can safely lower donor-specific antibodies (DSAs) in adults with blood cancers who are at high risk of rejecting a stem cell transplant. Participants receive the drug before standard transplant preparation to reduce DSA levels enough to al…

This study is testing whether a second dose of a CAR T-cell therapy called Axi-Cel is safe for people with a type of blood cancer called large B-cell lymphoma that is hard to treat. About 20 adults who have already had standard CAR T treatment but are at high risk of their cancer…

This study tests a mix of six drugs (ViPOR-P) in people with B-cell lymphoma that came back or didn't respond to prior treatment. The goal is to see if the combination is safe and can shrink tumors. Up to 55 adults will receive up to six 21-day cycles of oral pills and IV infusio…

This early-stage study tests a new drug called KSV01 in 18 adults with diffuse large B-cell lymphoma that has come back or not responded to prior treatment. The main goal is to check safety and find the right dose. Researchers will monitor side effects and look for signs that the…

This study tests a combination of three drugs—epcoritamab, zanubrutinib, and rituximab—in people with follicular lymphoma or marginal zone lymphoma that has come back or not responded to prior treatment. The goal is to see how well the combo works at shrinking tumors and to check…

This study tests a treatment using donor immune cells (CAR-NK cells) designed to attack cancer. The specific target on the cancer cells is chosen based on a biopsy of the tumor or a blood test. The goal is to see if this approach is safe and can shrink or control advanced solid t…

This early-phase study tests a new drug called SB-4826 in adults with advanced solid tumors or non-Hodgkin lymphoma. The main goal is to find a safe dose and see if it shrinks tumors. Some lymphoma patients will also get the drug combined with rituximab. Participants take SB-4826…

This study tests whether giving a CMV vaccine to stem cell donors can protect transplant recipients from CMV infection. Donors receive the vaccine before donating stem cells, and the immunity is passed to the patient. The trial involves 216 people with blood cancers and aims to r…

This early-phase trial tests a vaccine (CMV-MVA Triplex) given to both stem cell donors and recipients to boost immunity against cytomegalovirus (CMV) and prevent active infection after transplant. About 46 people with various blood cancers or disorders will take part. The goal i…

This study tests whether a medicine called XEMBIFY, given every two weeks alongside standard care, can reduce serious bacterial infections in adults with certain blood cancers (chronic lymphocytic leukemia, multiple myeloma, or non-Hodgkin lymphoma) who also have low antibody lev…

This study looks at whether a Mediterranean diet and exercise program can help lymphoma patients finish their chemotherapy and feel better during treatment. About 140 adults with Hodgkin or non-Hodgkin lymphoma who are starting chemotherapy will take part. The goal is to see if t…

This study tests whether a tailored physical activity program can help preserve exercise capacity, heart function, memory, and quality of life in adults (ages 18-85) with Hodgkin or non-Hodgkin lymphoma or stage I-III breast cancer who are undergoing chemotherapy or other cardiot…

This study looks at whether firefighters' exposure to dangerous chemicals on the job raises their risk of developing blood cancers. Researchers will test blood samples from 300 firefighters in Charlotte, NC, for early signs of cancer, such as abnormal blood cells or proteins. The…

This study interviews Spanish-speaking families of children with leukemia or lymphoma to understand their experiences and satisfaction with care. The goal is to identify common needs and barriers caused by language differences, and to explore interest in a home telemedicine suppo…

This study is testing whether daily voice recordings made on a smartphone can help doctors spot early signs of a brain-related side effect called ICANS in people receiving CAR T-cell therapy for non-Hodgkin lymphoma or multiple myeloma. About 20 participants will record their voi…

This study follows 2000 adults with newly diagnosed cancers (breast, colorectal, lung, melanoma, or lymphoma) who are receiving chemotherapy or immunotherapy. Researchers will track whether using cannabis or cannabinoids helps reduce symptoms like pain, nausea, or fatigue, and al…

This study is testing whether an artificial intelligence tool can help match cancer patients to clinical trials they might be eligible for. Researchers will enroll up to 50,000 people with various types of cancer and use the AI to suggest trials. The goal is to see if this approa…

This study looks at how the body processes venetoclax when the tablets are crushed and mixed into a liquid for children and young adults with blood cancers like leukemia or lymphoma. About 30 participants who already take venetoclax this way will have their blood levels measured.…

This study looks at whether a tailored exercise program can slow down the aging process in people aged 50 and older who have survived blood cancers like leukemia or lymphoma. Researchers want to find out how much and what type of exercise is needed to make a difference. The goal …

This study looks at how social and genetic factors impact the long-term health of young adults who survived Hodgkin or non-Hodgkin lymphoma. Researchers will collect blood samples and health information from 2000 survivors to understand why some face more health problems after tr…

This early-phase study is testing a new imaging agent called [68Ga]-pentixafor to see how well it lights up certain blood cancers and related disorders on PET/CT scans. About 30 adults with non-Hodgkin lymphoma, multiple myeloma, or histiocytic neoplasms will receive the agent an…

This study looks at whether peer-to-peer education and support can help more young people (ages 15-39) living with HIV get screened for and treated for certain cancers. About 4,100 participants in Zambia will take part. The goal is to see if this approach increases the number who…

This study looks at tumor samples from 50 people who developed a second cancer after receiving a BMS-made CAR-T cell therapy. Researchers will test whether the original treatment's genes are present in the new tumor. The goal is to understand if the therapy played a role, not to …

This research study aims to discover new genes that may increase the risk of childhood cancer. Researchers will collect blood samples and health information from 1,500 people in families where cancer clusters. The goal is to build a registry and sample bank to help future diagnos…

This study looks at how the bodies of children and young adults (ages 6-25) with Hodgkin or non-Hodgkin lymphoma break down certain drugs. Researchers will give small doses of probe medications during regular hospital visits and take blood samples to measure metabolism. The goal …

This early-phase study tests a new PET imaging tracer called 64Cu-GRIP B in 32 adults with relapsed or hard-to-treat non-Hodgkin lymphoma who are receiving CAR-T therapy. The tracer aims to detect a protein released by active immune cells, which may help identify tumors that will…

This study follows 250 young adults (ages 18-39) recently diagnosed with cancer to see how their social relationships and physical activity change over time and affect their quality of life. Researchers will track hospitalizations, treatment details, exercise habits, and well-bei…